作者: Sergio E. Starkstein , Simone Brockman , Brad Hayhow
DOI: 10.1007/978-1-4471-2428-3_3
关键词: Reboxetine 、 Depression (differential diagnoses) 、 Internal medicine 、 Randomized controlled trial 、 Incidence (epidemiology) 、 Nortriptyline 、 Quality of life 、 Citalopram 、 Stroke 、 Medicine
摘要: Poststroke depression (PSD) is among the most common neuropsychiatric sequelae of stroke. Cross-sectional studies have demonstrated that about one-third patients develop during acute stage after stroke and more than 50 % suffer at some later point. PSD strongly associated with negative outcomes, such as increased length hospital stay, severity neurological functional deficits, severe cognitive worse quality life, mortality. Randomized controlled trials efficacy nortriptyline, citalopram, reboxetine to treat PSD. Recent also suggest prophylactic treatment antidepressants may significantly decrease incidence PSD, although research in this area needed.